Contribute Try STAT+ Today

Getting the right drug to the right place at the right time has been the leading principle of precision medicine, guided by GPS-like genomic advances to engineer targeted therapies. New research from the Whitehead Institute suggests more traditional chemotherapy drugs could also be fine-tuned to hit smaller targets within cells, possibly boosting their efficacy.

Cells contain organelles such as mitochondria, which churn out energy, and ribosomes, which manufacture proteins, but there are also as many as 20 other complex compartments in the nucleus that lack membranes but carry out cellular duties. Proteins cluster within these droplets, called condensates. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.